<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37709528</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003475</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003475</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Type I interferon (IFN) plays a role in the pathogenesis of systemic lupus erythematosus (SLE), but insufficient attention has been directed to the differences in IFN responses between ancestral populations. Here, we explored the expression of the interferon gene signatures (IGSs) in SLE patients of European ancestry (EA) and Asian ancestry (AsA).</AbstractText><AbstractText Label="METHODS">We used gene set variation analysis with multiple IGS encompassing the response to both type 1 and type 2 IFN in isolated CD14+ monocytes, CD19+B cells, CD4+T cells and Natural Killer (NK) cells from patients with SLE stratified by self-identified ancestry. The expression of genes upstream of the IGS and influenced by lupus-associated risk alleles was also examined. Lastly, we employed machine learning (ML) models to assess the most important features classifying patients by disease activity.</AbstractText><AbstractText Label="RESULTS">AsA patients with SLE exhibited greater enrichment in the IFN core and IFNA2 IGS compared with EA patients in all cell types examined and, in the presence and absence of autoantibodies. Overall, AsA patients with SLE demonstrated higher expression of genes upstream of the IGS than EA counterparts. ML with feature importance analysis indicated that IGS expression in NK cells, anti-dsDNA, complement levels and AsA status contributed to disease activity.</AbstractText><AbstractText Label="CONCLUSIONS">AsA patients with SLE exhibited higher IGS than EA patients in all cell types regardless of autoantibody status, with enhanced expression of genetically associated genes upstream of the IGS potentially contributing. AsA, along with the IGS in NK cells, anti-dsDNA and complement, independently influenced SLE disease activity.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rector</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>AMPEL Biosolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-7530-6130</Identifier><AffiliationInfo><Affiliation>AMPEL BioSolutions LLC, Charlottesville, Virginia, USA kate.owen@ampelbiosolutions.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachali</LastName><ForeName>Prathyusha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AMPEL Biosolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AMPEL Biosolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdany</LastName><ForeName>Jinoos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medicine/Rheumatology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'era</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grammer</LastName><ForeName>Amrie C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>AMPEL Biosolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsky</LastName><ForeName>Peter E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>AMPEL Biosolutions LLC and the RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 DP006486</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Polymorphism, Genetic</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37709528</ArticleId><ArticleId IdType="pmc">PMC10503349</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003475</ArticleId><ArticleId IdType="pii">rmdopen-2023-003475</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol 2013;8. 10.2217/ijr.13.58</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/ijr.13.58</ArticleId><ArticleId IdType="pmc">PMC3885171</ArticleId><ArticleId IdType="pubmed">24416080</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, et al. . High levels of circulating Interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 2019;21:107. 10.1186/s13075-019-1878-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard EL, Pisetsky DS, Lipsky PE. Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. Ann Rheum Dis 2022;81:632&#x2013;43. 10.1136/annrheumdis-2021-221662</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221662</ArticleId><ArticleId IdType="pubmed">35115332</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto T, Dorschner J, Jolly M, et al. . Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds. Lupus Sci Med 2018;5:e000246. 10.1136/lupus-2017-000246</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000246</ArticleId><ArticleId IdType="pmc">PMC5786906</ArticleId><ArticleId IdType="pubmed">29387437</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazewski C, Perez RE, Fish EN, et al. . Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways. Front Immunol 2020;11:606456. 10.3389/fimmu.2020.606456</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.606456</ArticleId><ArticleId IdType="pmc">PMC7719805</ArticleId><ArticleId IdType="pubmed">33329603</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds JA, Briggs TA, Rice GI, et al. . Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res Ther 2019;21:147. 10.1186/s13075-019-1929-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1929-4</ArticleId><ArticleId IdType="pmc">PMC6567906</ArticleId><ArticleId IdType="pubmed">31200750</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalina MD, Bachali P, Geraci NS, et al. . Gene expression analysis delineates the potential roles of multiple Interferons in systemic lupus erythematosus. Commun Biol 2019;2:140. 10.1038/s42003-019-0382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0382-x</ArticleId><ArticleId IdType="pmc">PMC6478921</ArticleId><ArticleId IdType="pubmed">31044165</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalina MD, Bachali P, Yeo AE, et al. . Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight 2020;5:e140380. 10.1172/jci.insight.140380</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140380</ArticleId><ArticleId IdType="pmc">PMC7455079</ArticleId><ArticleId IdType="pubmed">32759501</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211&#x2013;21. 10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiu G, Rasmussen TK, Tsai BL, et al. . High interferon signature leads to increased Stat1/3/5 phosphorylation in PBMCs from SLE patients by single cell mass cytometry. Front Immunol 2022;13:833636. 10.3389/fimmu.2022.833636</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.833636</ArticleId><ArticleId IdType="pmc">PMC8851522</ArticleId><ArticleId IdType="pubmed">35185925</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Richman L, Higgs BW, et al. . Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha Monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785&#x2013;96. 10.1002/art.24557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24557</ArticleId><ArticleId IdType="pubmed">19479852</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J, Laval G, Patin E, et al. . Evolutionary genetic dissection of human Interferons. J Exp Med 2011;208:2747&#x2013;59. 10.1084/jem.20111680</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111680</ArticleId><ArticleId IdType="pmc">PMC3244034</ArticleId><ArticleId IdType="pubmed">22162829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariuki SN, Franek BS, Kumar AA, et al. . Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R151. 10.1186/ar3101</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3101</ArticleId><ArticleId IdType="pmc">PMC2945049</ArticleId><ArticleId IdType="pubmed">20659327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Molineros JE, Looger LL, et al. . High-density genotyping of immune-related Loci identifies new SLE risk variants in individuals with Asian ancestry. Nat Genet 2016;48:323&#x2013;30. 10.1038/ng.3496</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3496</ArticleId><ArticleId IdType="pmc">PMC4767573</ArticleId><ArticleId IdType="pubmed">26808113</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen KA, Bell KA, Price A, et al. . Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus eyrthematosus patients of Asian and European ancestry. Sci Rep 2023;13:5339. 10.1038/s41598-023-32569-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-32569-6</ArticleId><ArticleId IdType="pmc">PMC10067935</ArticleId><ArticleId IdType="pubmed">37005464</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott M, Jones S, Koelmeyer R, et al. . Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med 2022;9:e000625. 10.1136/lupus-2021-000625</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000625</ArticleId><ArticleId IdType="pmc">PMC8867321</ArticleId><ArticleId IdType="pubmed">35197305</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoletti G, Lanata CM, Trupin L, et al. . Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. Commun Biol 2021;4:488. 10.1038/s42003-021-02000-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02000-9</ArticleId><ArticleId IdType="pmc">PMC8060402</ArticleId><ArticleId IdType="pubmed">33883687</ArticleId></ArticleIdList></Reference><Reference><Citation>Labonte AC, Kegerreis B, Geraci NS, et al. . Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS One 2018;13:e0208132. 10.1371/journal.pone.0208132</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0208132</ArticleId><ArticleId IdType="pmc">PMC6298676</ArticleId><ArticleId IdType="pubmed">30562343</ArticleId></ArticleIdList></Reference><Reference><Citation>Daamen AR, Bachali P, Owen KA, et al. . Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Sci Rep 2021;11:7052. 10.1038/s41598-021-86002-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86002-x</ArticleId><ArticleId IdType="pmc">PMC8007747</ArticleId><ArticleId IdType="pubmed">33782412</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen KA, Price A, Ainsworth H, et al. . Analysis of trans-ancestral SLE risk Loci identifies unique biologic networks and drug targets in African and European Ancestries. Am J Hum Genet 2020;107:864&#x2013;81. 10.1016/j.ajhg.2020.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.09.007</ArticleId><ArticleId IdType="pmc">PMC7675009</ArticleId><ArticleId IdType="pubmed">33031749</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, et al. . Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022;81:951&#x2013;61. 10.1136/annrheumdis-2021-221425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford) 2017;56:i67&#x2013;77. 10.1093/rheumatology/kew399</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew399</ArticleId><ArticleId IdType="pubmed">27940583</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Kim K, Suetsugu H, et al. . Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Ann Rheum Dis 2022;81:1273&#x2013;80. 10.1136/annrheumdis-2022-222345</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222345</ArticleId><ArticleId IdType="pmc">PMC9380500</ArticleId><ArticleId IdType="pubmed">35609976</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, De S, Nelson V, et al. . Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J Clin Invest 2020;130:6700&#x2013;17. 10.1172/JCI120288</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI120288</ArticleId><ArticleId IdType="pmc">PMC7685739</ArticleId><ArticleId IdType="pubmed">32897883</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q, Zhao J, Qian X, et al. . Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 2011;63:749&#x2013;54. 10.1002/art.30193</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30193</ArticleId><ArticleId IdType="pmc">PMC3063317</ArticleId><ArticleId IdType="pubmed">21360504</ArticleId></ArticleIdList></Reference><Reference><Citation>Alunno A, Padjen I, Fanouriakis A, et al. . Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 2019;8:898. 10.3390/cells8080898</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080898</ArticleId><ArticleId IdType="pmc">PMC6721755</ArticleId><ArticleId IdType="pubmed">31443172</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bruce IN, D&#xf6;rner T, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023;401:1011&#x2013;9. 10.1016/S0140-6736(22)02546-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId><ArticleId IdType="pubmed">36848919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Deodhar AA, van der Heijde D, et al. . Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 2022;81:815&#x2013;22. 10.1136/annrheumdis-2021-221664</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221664</ArticleId><ArticleId IdType="pmc">PMC9120409</ArticleId><ArticleId IdType="pubmed">35241426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36&#x2013;49. 10.1038/nri3581</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstein I, Klein R, Okawa J, et al. . The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012;166:971&#x2013;5. 10.1111/j.1365-2133.2012.10825.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2012.10825.x</ArticleId><ArticleId IdType="pmc">PMC3336025</ArticleId><ArticleId IdType="pubmed">22242767</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Singh S, Tesfasyone H, et al. . Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980&#x2013;9. 10.1177/0961203309105529</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309105529</ArticleId><ArticleId IdType="pmc">PMC4752166</ArticleId><ArticleId IdType="pubmed">19762399</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolt-Marticorena C, Bonventi G, Lubovich A, et al. . Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440&#x2013;6. 10.1136/ard.2008.093146</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.093146</ArticleId><ArticleId IdType="pubmed">18772188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M, Ota M, Takeshima Y, et al. . Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell 2022;185:3375&#x2013;89. 10.1016/j.cell.2022.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.021</ArticleId><ArticleId IdType="pubmed">35998627</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz E, Adawi M, Lavi I, et al. . Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity. Rheumatol Int 2007;27:941&#x2013;5. 10.1007/s00296-007-0324-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-007-0324-7</ArticleId><ArticleId IdType="pubmed">17639400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AHJ, Strand V, Sen DP, et al. . Association of blood concentrations of complement split product IC3B and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol 2019;71:420&#x2013;30. 10.1002/art.40747</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40747</ArticleId><ArticleId IdType="pmc">PMC6393208</ArticleId><ArticleId IdType="pubmed">30294950</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpintero MF, Martinez L, Fernandez I, et al. . Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 2015;24:1057&#x2013;66. 10.1177/0961203315575586</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315575586</ArticleId><ArticleId IdType="pmc">PMC4529793</ArticleId><ArticleId IdType="pubmed">25736140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, Xu S. Population genomics of East Asian ethnic groups. Hereditas 2020;157:49. 10.1186/s41065-020-00162-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41065-020-00162-w</ArticleId><ArticleId IdType="pmc">PMC7724877</ArticleId><ArticleId IdType="pubmed">33292737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>